Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

ClinicalTrials.gov ID: NCT01178073

Public ClinicalTrials.gov record NCT01178073. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 7:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Study identification

NCT ID
NCT01178073
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
610 participants

Conditions and interventions

Interventions

  • ambrisentan Drug
  • tadalafil Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2010
Primary completion
Jul 30, 2014
Completion
Jul 30, 2014
Last update posted
Sep 12, 2017

2010 – 2014

United States locations

U.S. sites
61
U.S. states
29
U.S. cities
53
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35294
GSK Investigational Site Mobile Alabama 36617
GSK Investigational Site Phoenix Arizona 85012
GSK Investigational Site Tucson Arizona 85724
GSK Investigational Site La Jolla California 92093
GSK Investigational Site Los Angeles California 90073
GSK Investigational Site Sacramento California 95817
GSK Investigational Site Torrance California 90502
GSK Investigational Site Aurora Colorado 80045
GSK Investigational Site Gainesville Florida 32610
GSK Investigational Site Jacksonville Florida 32209
GSK Investigational Site Kissimmee Florida 34741
GSK Investigational Site Orlando Florida 32803
GSK Investigational Site Weston Florida 33331
GSK Investigational Site Atlanta Georgia 30322
GSK Investigational Site Decatur Georgia 30030
GSK Investigational Site Oakbrook Terrace Illinois 60181
GSK Investigational Site Carmel Indiana 46032
GSK Investigational Site Iowa City Iowa 52242
GSK Investigational Site Kansas City Kansas 66160
GSK Investigational Site New Orleans Louisiana 70112
GSK Investigational Site Portland Maine 04102
GSK Investigational Site Baltimore Maryland 21201
GSK Investigational Site Boston Massachusetts 02111
GSK Investigational Site Boston Massachusetts 02115
GSK Investigational Site Boston Massachusetts 02118
GSK Investigational Site Springfield Massachusetts 01199
GSK Investigational Site Ann Arbor Michigan 48109
GSK Investigational Site Detroit Michigan 48201
GSK Investigational Site Troy Michigan 48085
GSK Investigational Site St Louis Missouri 63110
GSK Investigational Site Omaha Nebraska 68131
GSK Investigational Site Morristown New Jersey 07962
GSK Investigational Site Newark New Jersey 07112
GSK Investigational Site New Hyde Park New York 11040
GSK Investigational Site New York New York 10003
GSK Investigational Site New York New York 10019
GSK Investigational Site New York New York 10021
GSK Investigational Site New York New York 10032
GSK Investigational Site Rochester New York 14623
GSK Investigational Site Asheville North Carolina 28803
GSK Investigational Site Chapel Hill North Carolina 27599
GSK Investigational Site Cincinnati Ohio 45219
GSK Investigational Site Cincinnati Ohio 45267
GSK Investigational Site Cleveland Ohio 44195
GSK Investigational Site Columbus Ohio 43221
GSK Investigational Site Portland Oregon 97220
GSK Investigational Site Philadelphia Pennsylvania 19104
GSK Investigational Site Philadelphia Pennsylvania 19140
GSK Investigational Site Pittsburgh Pennsylvania 15212
GSK Investigational Site Pittsburgh Pennsylvania 15213
GSK Investigational Site Providence Rhode Island 02903
GSK Investigational Site Nashville Tennessee 37232
GSK Investigational Site Dallas Texas 75390
GSK Investigational Site Houston Texas 77030
GSK Investigational Site Temple Texas 76508
GSK Investigational Site Murray Utah 84157
GSK Investigational Site Charlottesville Virginia 22908
GSK Investigational Site Norfolk Virginia 23507
GSK Investigational Site Richmond Virginia 23298
GSK Investigational Site Milwaukee Wisconsin 53215

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 82 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01178073, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 12, 2017 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01178073 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →